AI医疗公司Carlsmed(CARL.US)IPO定价15美元/股 超出区间上限

Company Overview - Carlsmed, a medical technology company specializing in personalized spinal surgery using artificial intelligence, completed an IPO raising $100.5 million by issuing 6.7 million shares at $15 each [1] - The company is headquartered in Carlsbad, California, and has a market capitalization of approximately $397.7 million based on the disclosed number of shares [1] - Major institutional investors include B Capital Group and US Venture Partners, with their ownership diluted to 26.3% and 21.2% respectively post-IPO [1] Financial Performance - For the first three months of 2025, Carlsmed reported revenues of $10.2 million and a net loss of $5.7 million, compared to revenues of $5.1 million and a net loss of $5.4 million in the same period last year [2] - As of March 2025, approximately 177 surgeons have utilized Carlsmed's platform for surgeries, a significant increase from 103 users in the previous year [2] Market Context - The IPO occurs amid a downturn in the U.S. healthcare IPO market, with only $2.1 billion raised by new listings in 2025, nearly a 50% decrease compared to the same period in 2024 [2] - The IPO is underwritten by major financial institutions including Bank of America, Goldman Sachs, and Piper Sandler, with shares set to trade on the Nasdaq Global Select Market under the ticker symbol CARL [2] Technology and Future Plans - Carlsmed's aprevo technology platform is currently approved for lumbar fusion surgeries, with plans to develop solutions for cervical fusion surgeries expected to be commercialized by 2026 [1]